Fundraising Fox
Westlake Village BioPartners
Venture capitalLos Angeles · Pre-Seed–Series A · 11 people tracked
Also known as WESTLAKE BIOPARTNERS, LLC
Find your way into Westlake Village BioPartners
5,597 people in our graph share verified history with the Westlake Village BioPartners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
The firm takes a people-first, company-creation approach to life science investing, crafting and incubating a concentrated portfolio of biotech companies around world-class entrepreneurs. Deeply embedded in the Los Angeles biotech ecosystem it helped catalyze, it is intentionally scaled to offer close, hands-on relationships with founders, guiding companies from ideation and preclinical research through clinical and commercial impact. The firm emphasizes empowering the right people, providing personal attention, capital, and access to a complementary network of innovation and community, with the goal of turning scientific breakthroughs into life-saving medicines that address the greatest unmet patient needs in California and beyond.
Source: firm website, verified Sep 29, 2026.
Team · 11 people
from the firm's website & public directories
What they invest in
from 28 of 37 portfolio companiesBiotech ×25Healthtech ×16Medical Devices ×10AI & Machine Learning ×7Digital Health ×7Deep Tech ×5Enterprise Software ×1Fintech ×1
HQs:United States×22
Investments · 37 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 62024 · 22023 · 32022 · 22021 · 62020 · 22019 · 12018 · 124 dated
Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology.
BiotechDigital HealthHealthtechMenlo Park, US
Rekha Hemrajani(Executive Officer)inMerdad Parsey(Executive Officer, Director)inDavid Happel(Chief Executive Officer & Director)Andreas Grauer(Chief Medical Officer)inThierry Chauche(Chief Financial Officer)inMarie O'Farrell(Chief Scientific Officer)in
Board seatBeth Seidenberg· per SEC Form D · $80M raise · filed Jan 2021
Co-investorsAltium CapitalHM Venture PartnersKleiner PerkinsNew Enterprise Associates (NEA)BAM ElevateBiotechnology Value Fund+1 more
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalHBM Healthcare InvestmentsHBM PartnersNextech InvestOrbiMedSamsara BioCapital+3 more
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.
BiotechEmeryville, US
Warner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)in
Co-investorsBain Capital Life SciencesVida VenturesGilead SciencesKleiner PerkinsOxford Finance LLCRTW Investments L.P.+1 more
Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids.
BiotechDeep TechDigital HealthMedical Devices
Viviana GradinaruNick Goeden, Ph.D.(Co-founder)Nicholas Flytzanis(Co-founder)in
Co-investorsVersant Ventures
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
BiotechHealthtechBoulder, US
Joey Azofeifa(Founder)inLaura Norris(Executive Officer, Director)inTimothy Read(Executive Officer, Director)Eric Martin(Executive Officer)in
BoardAmit Mehta(Director)
Board seatDavid AllisonMira Chaurushiya· per SEC Form D · $35.3M raise · filed Nov 2025
Co-investorsFifty YearsFundersClubTau VenturesvenBio PartnersY CombinatorAlamo Angels+8 more
Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Ken Drazan(Founder)James Ahlers(Executive Officer)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)
BoardValentin Barsan(Director)Sean Parker(Director)
Board seatBeth Seidenberg· per SEC Form D
Co-investorsARCH Venture PartnersHitachi VenturesKleiner PerkinsLuma GroupOUP (Osage University Partners)SoftBank Vision Fund+2 more
Impel Pharmaceuticals develops therapies for diseases with high unmet medical needs by pairing established drugs with its proprietary upper-nasal drug delivery technology.
BiotechHealthtechMedical DevicesSeattle, US
John D. Hoekman(Executive Officer, Director)in
BoardMichael Hite(Director)Stewart Parker(Director)
Board seatDavid Allison· per SEC Form D · $1.9M raise · filed Apr 2021
Co-investors5AM VenturesB Capital GroupvenBio Global StrategicvenBio Partners
.jpeg){kind=logo}
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardJim Tananbaum(Director)inDeborah Palestrant(Director)inKevin Raidy(Director)
Board seatBeth Seidenberg· per SEC Form D
Co-investors5AM VenturesAccess BiotechnologyAscenta CapitalForesite CapitalKern Capital, LLCSanofi Ventures
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in
Board seatDavid Allison· per SEC Form D
Co-investors5AM VenturesOrbiMedSamsara BioCapitalvenBio PartnersVivo CapitalRTW Investments L.P.+1 more
Soteria Biotherapeutics develops protein-based biotherapeutics and small molecules using its LITE Switch technology platform for drug discovery and development across oncology, immune-oncology, and inflammatory disease indications.
BiotechDeep TechHealthtechMedical DevicesWellness & FitnessSan Francisco, US
Jim Wells(Co-founder, Scientific Advisory Board Chair)Kristine M Ball(Executive Officer, Director)inZachary Hill(Executive Officer, Director)in
BoardNisha Marathe(Director)Keno Gutierrez(Director)in
Board seatDavid Allison· per SEC Form D
Co-investors5AM VenturesNovartis Venture FundRoche Venture FundVersant VenturesBioGeneration Ventures
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Board seatBeth Seidenberg· per SEC Form D · $125M raise · filed Oct 2025
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesAgent Capital+10 more
3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets.
AI & Machine LearningBiotechHealthtechMedical DevicesSouth San Francisco, US
K. Christopher GarciaMarvin Gee(Founder)in
Co-investorsAsset Management CompanyCRV (Charles River Ventures)Menlo VenturesOS FundStarlight VenturesThiel Capital
AI & Machine LearningBiotechDigital HealthHealthtech
Co-investorsDecheng CapitalSamsara BioCapitalvenBio PartnersAccess IndustriesKleiner Perkins
Akamis Bio develops oncolytic immunotherapies for colorectal cancer treatment, aiming to offer alternatives to surgery that preserve patient function and quality of life.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsARCH Venture PartnersSR One Capital Management
AllRock Bio is a drug development company advancing novel therapies for pulmonary hypertension, interstitial lung diseases, and other fibrotic conditions.
BiotechNatick, US
Catherine Pearce(CEO & Founder)inDHSc(Founder)Justin R Thompson(Founder)in
Co-investorsVersant VenturesWestlake BioPartners
Borealis develops RNA medicines to treat kidney diseases.
BiotechDigital Health
Co-investorsVersant Ventures
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Adam Rosenthal(Co-founder and former CEO; Director)inQuehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)Kathy Dong(President, Chief Executive Officer and Director)in
BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)
Co-investorsHBM Healthcare InvestmentsHBM PartnersOrbiMedRA CapitalKleiner PerkinsNVIDIA
BiotechSan Diego, US
Kevin Forrest, Ph.D.(Executive Officer, Director)
BoardClare Ozawa, Ph.D.(Director)Beth Seidenberg, M.D.(Director)
Co-investorsKleiner PerkinsOsage University PartnersVersant Ventures
Magnetic Particle Imaging (MPI) is an imaging technology that detects iron oxide nanoparticle tracers using time-varying magnetic fields to create medical images with high contrast and sensitivity.
Deep TechHealthtechMedical Devices
Co-investors5AM VenturesEvolution VC PartnersInnolinks VenturesSand Hill AngelsShangBay Capital LLCCelesta Capital
Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.
AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US
Nancy Stagliano(CEO)in
Co-investorsHBM Healthcare InvestmentsHBM PartnersKleiner PerkinsSoftBank GroupSoftBank Vision FundACORN BIOVENTURES+2 more
Oorja Bio is a biotechnology company developing therapies focused on fibrotic disease, aiming to repair, reverse, and remodel fibrosis.
BiotechHealthtech
Sujay Kango(Chief Executive Officer & Founder)inJanethe Pena(Chief Medical Officer & Founder)inConnie Coulomb(Chief Business Officer & Founder)in
Co-investorsAndreessen HorowitzKleiner PerkinsWestlake BioPartners
Qumis provides an AI platform built for insurance coverage attorneys and law firms that analyzes complex insurance policies and programs, producing cited, confidence-scored comparisons, checklists, opinions, and client-ready deliverables.
AI & Machine LearningInsurTechLegalTechChicago, US
Shivam Sinha(Executive Officer, Director)Dan Schuleman(Executive Officer, Director)
BoardBrian McLoughlin(Director)inNeenah Jain(Director)in
Co-investorsAmerican Family VenturesMTECH CAPITALArmory Square Ventures
BiotechMenlo Park, US
Brett Ewald(Executive Officer)inUmesh Gangadharmath(Executive Officer)inIstvan Molnar(Executive Officer)inYunfei Zhu(Executive Officer)Ana Kusnetzow(Executive Officer)inScott Struthers(Director)
Co-investorsDCVC (Data Collective)Frazier Life Sciences5AM VenturesDCVC BioFrazier Healthcare Partners
Recludix Pharma operates a drug discovery platform that combines custom DNA-encoded libraries (DELs), massively parallel structure-activity relationship analysis, structure-based design, and a family-wide SH2 domain screening panel.
AI & Machine LearningBiotechDeep TechHealthtechSan Diego, US
Nancy Whiting(CEO)in
Co-investorsAccess BiotechnologyNew Enterprise Associates (NEA)
Uprise builds AI-based financial tools aimed at small business owners, addressing their combined business and personal financial needs.
AI & Machine LearningEnterprise SoftwareFintechSaaSSan Francisco, US
Nanthakumar Muthusamy(Founder)inChris Goodmacher(Co-Founder)inJessica Chen Riolfi(Co-Founder & CEO)in
Co-investorsContraryGraham Walker VentureOxonian VenturesBlank VenturesDash FundHustle Fund+1 more
Vedana Therapeutics develops next-generation biologic medicines for migraine prevention, targeting PACAP and CGRP-independent pathways to address unmet needs in patients inadequately controlled by current therapies.
BiotechHealthtechMedical Devices
Co-investorsCanaan Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AllRockArsenalCinCor PharmaElectraExpansion TherapeuticsKateLatigoMeanwhileStarTmunityVega
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 4
3 IPOs · 1 acquisitionsSagimet BiosciencesNASDAQ: SGMTAlumisNASDAQ: ALMSKyverna TherapeuticsNASDAQ: KYTXAcelyrinacq. by Alumis
Portfolio news
latest coverage across their companiesOorja Bio · finsmes.com · May 20, 2026
Qumis · thesaasnews.com · Feb 20, 2026
Recludix · recludixpharma.com · Jan 12, 2026
Star Therapeutics · star-therapeutics.com · Sep 30, 2025
Neuron23 · finsmes.com · Jun 25, 2025
Frequently asked questions
- How many investments has Westlake Village BioPartners made?
- Westlake Village BioPartners has 37 tracked investments, 4 of which have exited, including 8 dated in the last 24 months.
- What stage does Westlake Village BioPartners invest at?
- Westlake Village BioPartners invests at the Pre-Seed, Seed, Series A stages.
- What is Westlake Village BioPartners's typical check size?
- Westlake Village BioPartners typically writes checks of $100K – $5M.
- What sectors does Westlake Village BioPartners focus on?
- Westlake Village BioPartners focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Westlake Village BioPartners located?
- Westlake Village BioPartners is headquartered in Los Angeles, US.
- Does Westlake Village BioPartners lead rounds?
- Westlake Village BioPartners typically participates in rounds rather than leading them.
- Who does Westlake Village BioPartners co-invest with?
- Westlake Village BioPartners most often shares deals with Kleiner Perkins, OrbiMed, SoftBank Vision Fund, among 21 tracked co-investors.
Media · Podcasts & interviews
featuring the teamSean Harper -- Westlake Village BioPartners
LA Venture · Sean Harper
Images
Co-investors · 13
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Celesta Capital is a venture capital firm that invests in deep tech companies at the forefront of science and engineering.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
BioGeneration Ventures is a European venture capital firm investing in early-stage biotech, medtech and life sciences companies developing novel therapeutics and medical technologies.
Frazier Healthcare Partners is a healthcare-focused private equity firm that partners with profitable, growing healthcare companies to drive scale and long-term value, pairing high-conviction investment themes with experienced executives.
Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.
▶1 more co-investors
Firms observed investing alongside Westlake Village BioPartners, from public investor directories. Shared companies are the overlap with Westlake Village BioPartners's recorded portfolio.
Similar investors
Future Positive Capital is a venture firm backing entrepreneurs building companies that address large-scale global challenges across health, sustainability and technology.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
InnoCom Bio Equities manages life science special purpose vehicles, offering investors a diversified portfolio of innovative life sciences technologies and providing seed capital to innovators and founders.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.